RxDoctor Payments Data

Philip Neiderer, DO

Internal Medicine · Carlisle, PANPI 1922093509

Payments from drug & device makers

$299in general payments, 2019–2025

Across 13 payments — averaging $23.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$93
  • Novo Nordisk$89
  • Pfizer$35
  • Supernus Pharmaceuticals, Inc.$24
  • Pacira Therapeutics, Inc.$20
  • Ferring Pharmaceuticals Inc.$15
  • plus $24 from 2 others

What the payments were for

  • Food & beverage$299100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$299 in reported general payments places this provider in the 60th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$184,415
Medicare patients
503
Services billed
2,346

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin216$190,740
EliquisApixaban169$163,622
XareltoRivaroxaban110$103,424
MounjaroTirzepatide69$71,790
JanuviaSitagliptin Phosphate45$50,085
RybelsusSemaglutide16$40,140
OzempicSemaglutide17$31,391
Trelegy ElliptaFluticasone/Umeclidin/Vilanter32$27,754
TrulicityDulaglutide21$26,584
FarxigaDapagliflozin Propanediol11$15,969
EntrestoSacubitril/Valsartan22$14,828
JanumetSitagliptin Phos/Metformin Hcl13$14,597
TradjentaLinagliptin18$14,294
MyrbetriqMirabegron12$12,945
LinzessLinaclotide17$11,735

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$11$205,034234 claims
PfizerEliquis$35$163,622169 claims
Lilly USA, LLCMounjaro, Trulicity$93$98,37390 claims
Novo NordiskRybelsus, Ozempic$89$71,53133 claims
MerckJanuvia, Janumet$13$64,68358 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Carlisle

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →